Saturday, December 20, 2025

Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Soma Gold: Q3 Earnings Impacted By Labour Strike

Thesis Gold: The Multi-Billion Dollar Lawyers-Ranch PFS

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Recommended

Northern Superior Shareholders Set To Receive Shares Of ONGold Resources Friday

Goliath Resources Sees Rob McEwen Increase Ownership Interest

Related News

Equinox Gold: BMO Lifts Target To $14.50

Earlier this week, Equinox Gold Corp. (TSX: EQX) reported its first quarter financial results for...

Friday, May 6, 2022, 11:56:01 AM

WeCommerce: Canaccord Lowers Price Target After Shopify Changes Advertising Rules

On November 22nd, WeCommerce (TSXV: WE) reported its third quarter financial results. The company reported...

Sunday, November 28, 2021, 05:04:00 PM

Cognetivity Neurosciences: Echelon Initiates Coverage With $0.85 Price Target

On Friday, Echelon Capital Markets initiated coverage on Cognetivity Neurosciences (CSE: CGN) with a speculative...

Monday, April 19, 2021, 10:36:00 AM

Aphria: Canaccord Anticipates Q2 2021 Revenue Of $156.3 Million

Aphria Inc (TSX: APHA) (NASDAQ: APHA) will be releasing their second-quarter fiscal 2021 financial results...

Tuesday, January 12, 2021, 11:57:00 AM

Stifel Raises Eguana Technologies Price Target To $0.90

Yesterday Stifel GMP raised their price target on Eguana Technologies (TSXV: EGT) from C$0.85 to...

Thursday, May 6, 2021, 04:21:00 PM